Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) EPS (Basic) (2016 - 2025)

vTv Therapeutics' EPS (Basic) history spans 11 years, with the latest figure at -$0.4 for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 20.0% year-over-year to -$0.4; the TTM value through Dec 2025 reached -$3.2, changed 0.0%, while the annual FY2025 figure was -$3.2, 0.0% changed from the prior year.
  • EPS (Basic) for Q4 2025 was -$0.4 at vTv Therapeutics, up from -$1.11 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.01 in Q2 2021 and bottomed at -$9.78 in Q4 2022.
  • The 5-year median for EPS (Basic) is -$0.75 (2024), against an average of -$1.59.
  • The largest annual shift saw EPS (Basic) crashed 27400.0% in 2021 before it surged 82.92% in 2023.
  • A 5-year view of EPS (Basic) shows it stood at -$8.19 in 2021, then dropped by 19.41% to -$9.78 in 2022, then soared by 82.92% to -$1.67 in 2023, then soared by 70.06% to -$0.5 in 2024, then rose by 20.0% to -$0.4 in 2025.
  • Per Business Quant, the three most recent readings for VTVT's EPS (Basic) are -$0.4 (Q4 2025), -$1.11 (Q3 2025), and -$0.92 (Q2 2025).